Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maralixibat long-term safety in cholestatic liver disease
NCT04168385Phase 2Completed
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Jan 2020
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of maralixibat in cholestatic liver disease (CLD), sponsored by Mirum Pharmaceuticals, Inc.. Started Jan 2020; status: completed.
02
Drugs
maralixibat
03
Conditions
cholestatic liver disease (CLD)
Beyond the preview
Go deeper on NCT04168385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04168385.